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remains poorly defined. We have reviewed the Mayo
Clinic experience for all cases of large cell carcinoma
managed by resection with curative intent over a 5-year
period and compared and contrasted our findings with
those in the literature for large cell carcinoma as well as
non–small cell carcinoma of the lung in general.
Patients and methods
A review of the records of the Mayo Clinic Rochester
Division of Thoracic Surgery for the period of January 1,
1982, through December 31, 1986, revealed 98 patients who
underwent surgical exploration for potentially resectable car-
cinomas for which a diagnosis of large cell carcinoma was
rendered on initial pathologic review of only sections stained
with hematoxylin and eosin. These patients comprised the ini-
tial study group, and their clinical records were retrospectively
reviewed, histologic sections re-evaluated, and 5-year follow-
up obtained.
After re-review of the original sections stained with hema-
toxylin and eosin, 20 cases were excluded from the study: 6
because there was insufficient histologic material for addi-
tional studies and 14 because of reclassification of the carci-
noma as one of the following: squamous cell, combined
small/large cell, adenosquamous, or adenocarcinoma.
L arge cell carcinoma is the least common subtype ofthe 4 major histologic subtypes of carcinoma of the
lung, comprising 10% or fewer of cases.1 Large cell
carcinoma has traditionally been classified as a
non–small cell lung carcinoma along with squamous
carcinoma and adenocarcinoma. The histologic diagno-
sis of large cell carcinoma is based on an absence of
glandular or squamous differentiation in tumor cells
that do not show features of small cell carcinoma.2
Some studies have suggested a dismal prognosis even
with apparently curative resection,3-5 but the prognosis
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Seventy-eight cases remained, and on all of these a battery
of histochemical and immunohistochemical staining was per-
formed. Digested periodic acid–Schiff and mucicarmine
stains were performed to look for evidence of intracellular
mucin production. In addition, the following immunohisto-
chemical studies were performed: keratin (AE1/AE3), carci-
noembryonic antigen (polyclonal and monoclonal), Leu-7,
chromogranin, synaptophysin, and S-100. The immunohisto-
chemical stains were graded semiquantitatively on a scale of
0 to 2+ for intensity of staining and on the basis of percent-
age of positive cells (25%, 50%, 75%, and 100%). 
Among the original 78 patients, there were 17 in whom sig-
nificant amounts of intracellular mucin were identified (arbi-
trarily as more than 3 cells in a single 100· high-power field);
these cases were reclassified as solid adenocarcinoma with
mucin production according to World Health Organization
(WHO) definition.2
Sixty-one cases of large cell carcinoma remained and these
comprised the final study group. The 17 patients with solid
adenocarcinoma with mucin production were also studied as
a comparison group. 
Survival probabilities were calculated with the use of the
Kaplan-Meier method from the day of surgery and included
patients dying in the postoperative period (defined as 30 days
or less from the day of operation or within the same hospital-
ization). Survival to first evidence of recurrent disease was
also calculated from the day of surgery. Ninety-five percent
confidence intervals were calculated for all survival esti-
mates. Survival curves were compared with log-rank tests. 
Comparisons of findings between the large cell carcinoma
group and the solid adenocarcinoma with mucin production
group were carried out with Wilcoxon rank-sum tests for con-
tinuous variables, Fisher’s exact tests for nominal variables,
and exact Wilcoxon rank-sum tests for ordered variables. 
Results
Information regarding gender, age, smoking history,
symptoms at diagnosis, anatomic location of disease,
complete resection rates, and surgical staging are sum-
marized in Table I. Recurrence and survival data are
summarized in Table II. Immunohistochemical find-
ings are summarized in Table III. 
Large cell carcinoma. One patient had a history of
silo filler disease, 1 was receiving steroids for rheuma-
toid arthritis, and 2 had received thoracic irradiation for
reasons unrelated to their large cell carcinomas.
One patient had had a previous bilobectomy (right
upper lobe and right middle lobe) for a stage I squamous
cell carcinoma (T2 N0 M0). This patient’s large cell car-
cinoma was identified 33 months after this resection. 
Twelve patients (19%) had undergone resection of 12
extrapulmonary malignant tumors (2 bladder carcino-
mas, 2 breast adenocarcinomas, 2 prostate carcinomas,
1 neurofibrosarcoma, 1 melanoma, 3 basal cell carci-
nomas, and 1 colorectal adenocarcinoma). No patient
had a history of chemotherapy before the diagnosis of
large cell lung carcinoma.
Sputum cytologic examination was performed in 31
patients (50%) and the results were positive in 4 (6%).
Bronchoscopic examination was performed in 42
patients (68%); brushings were positive for malignan-
cy in 13 patients (22%), washings were positive in 11
(18%), and biopsy specimens were positive in 23
(39%). Mediastinoscopic examination was performed
in 15 patients (24%) and the results were positive for
malignancy in 1. Thoracocentesis was performed once
(1%) and did not disclose malignancy. Transthoracic
needle biopsy was performed 8 times (13%) and was
positive for malignancy in 7 patients (11%).
One patient had received preoperative chemotherapy
and 2 preoperative radiotherapy for their large cell
carcinomas.
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Table I. Clinical features and follow-up data
Large Solid 
cell adenocarcinoma 
carcinoma with mucin production P value
No. of cases 61 17
Sex .74
Male 49 13
Female 12 4
Age (y) .84
Mean 62 61
Range 35-85 38-75
Positive smoking 98% 82% .03
history
Pack-years .10
Mean 60 50
Range 13-120 20-132
Symptoms
Cough 38% 12% .04
Hemoptysis 21% 12% .50
Pain 15% 12% 1.00
Weight loss 10% 0% .33
Pneumonia 8% 6% 1.00
Generalized 13% 0% .19
weakness
Tumor location 
Right upper lobe 41% 47%
Right middle lobe 7% 6%
Right lower lobe 13% 0%
Left upper lobe 30% 24%
Left lower lobe 10% 24%
Complete resection 85% 82% .72
Surgical staging .97
Stage I 51% (31/61) 47% (8/17)
Stage II 10% (6/61) 12% (2/17)
Stage IIIA 33% (20/61) 41% (2/17)
Stage IIIB 3% (2/61) 0%
Stage IV 3% (2/61) 0%
Complete resection was not possible in 9 patients
(14%). In the remaining 52 patients, the procedure per-
formed was wedge or segmental excision in 3 patients
(4%), lobectomy in 36 (59%), bilobectomy in 1 (1%),
and pneumonectomy in 12 (23%). 
One patient had a second primary pulmonary malig-
nant tumor identified at the time of resection for large
cell carcinoma. A small bronchioloalveolar carcinoma
was identified.
The mean hospital stay was 9.5 days (range 4-26
days; 10th percentile 5 days, 50th 8 days, 90th 19
days). There were 2 perioperative deaths (4%).
Recurrences occurred in 21 of the 52 patients who
underwent complete resection (40%) and were detect-
ed a mean of 275 days (range 37-1543 days) after
resection. Ninety percent of the recurrences were
detected within 15.7 months of the day of surgery (10th
percentile 1.9 months, 50th percentile 6.0 months, 90th
percentile 15.7 months). The site of first recurrence
(which could be simultaneous in more than 1 organ)
was brain in 7 (33%), bone in 6 (28%), local or pul-
monary in 4 (19%), lymph node in 1 (4%), liver in 1
(4%), and adrenal gland in 2 (9%).
Follow-up either to death or to December 31, 1991,
was 100%. Seventeen patients (27%) are alive without
evidence of disease. One patient (1%) is alive with
recurrent disease. In addition to the 2 postoperative
deaths, 28 patients (45%) have died with recurrent dis-
ease, 11 (18%) have died without evidence of recur-
rence, and 2 (3%) have died of unknown causes.
Solid adenocarcinoma with mucous production.
No patient had any significant occupational expo-
sure history of immunosuppression or prior thoracic
irradiation.
Two patients had had prior pulmonary malignant
tumors: 1 patient had a stage I (T1 N0 M0) adenocar-
cinoma of the right upper lobe 24 months before resec-
tion for solid adenocarcinoma with mucin production.
Another patient had a stage I squamous cell carcinoma
of the right upper lobe (T1 N0 M0) resected 37 months
before resection of a solid adenocarcinoma with mucin.
Two patients (12%) had undergone resection of 3
extrapulmonary malignant tumors (1 breast adenocar-
cinoma, 1 prostate carcinoma, and 1 colorectal adeno-
carcinoma). No patient had a history of chemotherapy
or radiation therapy before the diagnosis of malignant
lung disease.
Cytologic examination of sputum cytology was per-
formed in 8 patients (47%) and was positive in 1 (6%).
Bronchoscopic study was performed in 13 patients
(76%), brushings were positive for malignancy in 2
patients (12%), washings were positive in 2 (12%), and
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Table II. Follow-up
Percent free from recurrence*
Large cell Solid adenocarcinoma with 
(n = 52) mucin production (n = 14)
Three years Five years Three years Five years 
(95% CI); N (95% CI); N (95% CI); N (95% CI); N P value
Overall 59% (46-75); 23 56% (44-73); 21 42% (21-84); 4 32% (13-77); 3 .17
Stage I 76% (46-75); 18 72% (57-91); 17 46% (18-100); 2 23% (4-100); 1 .06
Stage II 42% (15-100); 2 42% (12-100); 1 100%; 1 100%; 1 .39
Stage IIIA 27% (11-66); 3 27 (11-66); 3 20% (4-100); 1 20 (4-100); 1 .57
Stage IIIB — — — — —
Stage IV 0% 0% — — —
Survival†
Large cell Solid adenocarcinoma 
(n = 61) with mucin (n = 17)
Overall 39% (29-54); 24 38% (27-52); 23 35% (19-67); 6 24% (10-55); 4 .19
Stage I 58% (43-78); 18 58% (43-78); 18 50% (25-100); 4 25% (8-83); 2 .07
Stage II 50% (23-100); 3 33% (11-100); 2 50% (134-100); 1 50%; (13-100; 1 .74
Stage IIIA 15% (5-43); 3 15% (5-43); 3 14% (2-88; 1 14% (2-88); 1 .60
Stage IIIB 0% 0% — — —
Stage IV 0% 0% — — —
*Deaths without recurrence censored.
†Deaths from any cause.
biopsy was positive in 3 (18%). Mediastinoscopy was
performed in 2 patients and was negative in both.
Neither thoracentesis nor transthoracic needle biopsy
was performed in this group of patients.
No patient received either chemotherapy or radio-
therapy as treatment for their lung carcinoma before
attempted resection. 
Complete resection was not possible in 3 patients
(18%). In the remaining 14 patients, the procedure per-
formed was wedge or segmental excision in 2 patients
(12%), lobectomy in 9 (53%), bilobectomy in 1 (6%),
and pneumonectomy in 2 (12%). 
Two patients had second primary pulmonary malig-
nant tumors identified at the time of resection for solid
adenocarcinoma with mucin, 1 showing an incidental
bronchioloalveolar carcinoma and 1 showing a separate
incidental adenocarcinoma.
The mean hospital stay was 8.6 days (range 4-15 days;
10th percentile 4 days, 50th percentile 7 days, 90th per-
centile 14 days). There was 1 perioperative death (6%).
Recurrences occurred in 8 of the 14 patients having
complete resection (57%) and were detected a mean of
376 days (range 75-1171 days) after resection. Ninety
percent of the recurrences were detected within 32.7
months of the day of surgery (10th percentile 2.5
months, 50th percentile 4.1 months). The site of first
recurrence (which could be simultaneous in more than
1 organ) was brain in 3 (21%), bone in 2 (14%), local
or pulmonary in 3 (21%), lymph node in 2 (14%), and
liver or adrenal gland in none (0%).
Follow-up either to death or to December 31, 1991,
was 100%. One patient (6%) is alive without evidence
of disease, and 1 patient (6%) is alive with recurrent
disease. In addition to 1 postoperative death, 10
patients (59%) have died with recurrent diseases, and 4
(23%) have died without evidence of recurrence.
Discussion
Large cell carcinoma of the lung, as defined by the
WHO,2 has traditionally represented a “wastebasket”
category into which cases of lung carcinoma were
placed when tissue did not show squamous or glandu-
lar differentiation (including mucin production) and
did not show features of small cell carcinoma. This
diagnosis is based on routine histologic findings,
although cases diagnosed as large cell carcinoma may
show features of differentiation (squamous, glandular,
or neuroendocrine) when studied immunohistochemi-
cally or ultrastructurally,6,7 but these studies are not
part of most routine pathology practices, and not part of
the WHO classification of lung tumors.2
Large cell carcinoma of the lung is usually included
among the other non–small cell carcinomas in clinical
studies; thus it has been difficult to determine whether
large cell carcinoma has significant clinical differences
from squamous cell carcinoma and adenocarcinoma.
Studies that both provide rigorous surgical staging and
clear histologic criteria for the diagnosis of large cell
carcinoma have characterized the prognosis for
patients with the disease as dismal.3 Even for com-
pletely resected stage I or II disease, the 5-year survival
has been estimated as between 0% and 21%.4 Our
results for survival after resection of large cell carcino-
ma are more encouraging: the 5-year survival for stage
I disease was 51%, for stage II 37%, and for stage IIIA
14%. We observed an overall recurrence rate of 40% at
5 years; 95% of these recurrences occurred within 2
years. This is similar to the recurrence rate of 41%
reported by Immerman and coworkers.5 The anatomic
pattern of recurrences seen in our series of large cell
carcinomas was also similar to the pattern of recur-
rences seen after resection of squamous and adenocar-
cinomas.5 Ideally, our data for patients with large cell
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Table III. Immunohistochemical findings
Large cell carcinoma (n = 61) Solid adenocarcinoma with mucin production (n = 17)
Antibody Positive Strongly positive Positive Strongly positive
Keratin (AE1/AE3) 95% 79% 100% 100%
CEA (polyclonal) 48% 28% 63% 26%
CEA (monoclonal) 26% 11% 37% 16%
S-100 (tumor cells) 10% 0% 26% 0%
S-100 + stromal histiocytes† — 46% — 53%
Chromogranin 20% 0% 0% 0%
Leu-7 5% 2% 0% 0%
Synaptophysin 11% 0% 0% 0%
CEA, Carcinoembryonic antigen.
*Immunohistochemical findings shown were based on the following scoring system: Positive = at least 25% of the cells showing 1+ staining (scored 0 to 2+); strong-
ly positive = at least 75% of the cells showing 2+ staining (scored 0 to 2+). 
†These positive cells may represent Langerhans type histiocytes.
carcinoma would be compared with series of patients
with squamous cell carcinoma and adenocarcinoma
from our institution during the same period, but these
studies have not been performed. It is difficult to directly
compare these results with previously published series
of surgically treated squamous carcinoma and adeno-
carcinoma because patient characteristics, preoperative
and postoperative therapies, and surgical techniques
vary. However, it is likely that the overall survival, time
to recurrence, and pattern of recurrence seen in our
patients with large cell carcinoma are comparable with
or only slightly worse at each stage than those previ-
ously published results for the resection of squamous
and adenocarcinoma.
Large cell carcinoma of the lung is separated from
solid adenocarcinoma with mucin production based on
the presence of mucin as demonstrated histochemical-
ly with mucin stains in the latter.2 Since immunohisto-
chemical and ultrastructural studies show that the
majority of large cell carcinomas do show some differ-
entiation (usually toward adenocarcinoma), it is not
surprising that a significant portion of cases diagnosed
as large cell carcinoma on routine hematoxylin-eosin
sections would be reclassified as solid adenocarcinoma
with mucin production based on the presence of intra-
cellular mucin. Personal experience suggests that
pathology laboratories do not routinely do mucin stains
in this situation (T.V.C., unpublished data). In our re-
review and histochemical study of 78 cases previously
characterized as large cell carcinoma, we reclassified
17 cases (22%) as solid adenocarcinoma with mucin
production on the basis of mucin stains. The clinical
features, follow-up, and survival data for patients with
large cell carcinoma and patients with solid adenocar-
cinoma with mucin production are summarized in
Tables I and II. As shown in Table I, there is little dif-
ference between the 2 groups in terms of sex, age,
smoking history, symptoms, tumor location, feasibility
of complete resection, or surgical staging. The slight
differences noted in smoking history and cough are
probably not important. As shown in Table II, recur-
rence and overall survival data are also not significant-
ly different between patients with large cell carcinoma
and solid adenocarcinoma with mucin production,
either overall or on a stage-for-stage basis. On the basis
of these findings, we question the necessity of doing
mucin stains to segregate a subgroup of solid adeno-
carcinoma with mucin production from “true” large
cell carcinoma other than for research purposes.
Finally, a number of studies have suggested that the
immunohistochemical demonstration of neuroen-
docrine markers in lung tumor tissue is associated with
a favorable prognosis, in terms of overall survival or
response to chemotherapy.8-10 The findings, however,
have not been uniform, and other studies suggest that
these features are not prognostically significant.12
Neuroendocrine differentiation generally has been
demonstrated immunohistochemically with one or
more of the following markers: neuron specific eno-
lase, chromogranin A, synaptophysin, and Leu-7. We
studied all 78 of our cases with 3 of these markers and
did not find correlation between the presence or
absence of positivity for these markers with either
recurrence or survival.
In conclusion, prior reports have suggested that large
cell carcinoma of the lung is a disease with an over-
whelmingly poor prognosis. Our review of a consecu-
tive series of patients seen and operated on at the Mayo
Clinic suggests that reasonable survivals can be
obtained for patients after complete resection of all
known disease. Furthermore, our data suggest that the
detailed characterization of pathologic tissue to allow
segregation of subgroups of histologic types does not
clearly define patient groups with such different out-
looks as to alter therapy.
We gratefully acknowledge Bev Pike for her help in typing
the manuscript and Duane Ilstrup and Cathy Schleck in the
Department of Biostatistics at Mayo Clinic Rochester for
their performance of the statistical studies and help in inter-
preting and displaying the data.
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THE THORACIC SURGERY FOUNDATION FOR RESEARCH AND EDUCATION
Harvard Executive Course
The next offering of the Harvard Executive Course, Understanding the New World of Health Care, will be
November 6-14, 1999. Applications from Harvard will be available in June 1999. Please contact Eleanor
Brimley at 617-496-1069. Alley-Sheridan Scholarship materials will be available from The Foundation at the
same time and can be obtained by contacting Lainie Castle at 312-644-6610, extension 4798.
Thanks to TSFRE 1998 Donors
In 1998, over 230 surgeons contributed nearly $490,000 in cash and new pledges to The Thoracic Surgery
Foundation. This is the largest number of surgeons to have given to The Foundation since its inception in
1993, as well as the greatest amount received from surgeons in a single year. The Foundation would like to
express its profound gratitude to these donors who have helped The Foundation further its mission of pro-
viding valuable support to promising young surgeons in the specialty and to health policy leaders.
Planned Giving Opportunities
If you have been thinking of making a charitable contribution to TSFRE, this may be the perfect time to
consider a planned gift. A carefully orchestrated donation made for the current or future benefit of The
Foundation, a planned gift often enables a donor to make a larger gift at a cost that is actually lower than if
an outright cash gift were made. It may also enable you to meet other personal financial goals while mak-
ing significant charitable gifts.
You may give to The Foundation through a revocable instrument, such as a bequest in your will, or through
an irrevocable agreement such as a charitable remainder trust. You may also give through a life insurance
policy, your retirement plan, or stock investments. Please consult with your attorney and financial planner
to determine the best giving vehicle for you.
For more information on making a planned gift to The Foundation, contact Frank Kurtz, TSFRE Executive
Director, at 312-644-6610 (telephone), 312-527-6635 (fax), or frank_kurtz@sba.com (e-mail).
